Understanding COPD pulmonary indications through biomarkers and the practicalities of reliable clinical trials will be a major focus as will hearing from a selection of pharmaceutical organisations currently developing scientific trials for COPD. Exclusive updates into formulation developments and the manufacturing of dry powder inhalation products, lymphoid follicles in COPD and ACOS (Asthma, COPD, Overlap Syndrome) will be just some of the conference highlights this year.
Speakers include:
• Frank Thielmann, Operational Lead, Inhalation New Solids, Novartis
• Philip Silkoff, Senior Medical Dir., Johnson & Johnson
• Stefano Petruzzelli, Chief Medical Officer & Dir., Global Clinical Development, Chiesi
• Sanjeeva Dissanayake, Head of Medical Sciences – Respiratory, Mundipharma
• Noel Snell, Dir. of Research, British Lung Foundation
• Geoff Down, Chief Medical Officer, Prosonix
• Konstantinos Kostikas, Medical Dir. Respiratory COPD Region Europe, Novartis
• Thomas Schlange, Senior Biomarker Expert, Bayer
• Matthew Sleeman, Senior Dir. of Biology, Respiratory, Inflammation & Autoimmunity, MedImmune
Reasons to attend:
• Gain insight into formulation developments and the manufacturing of dry powder inhalation products
• Evaluate COPD and comorbidities
• Learn about "first in class" inhaled drugs for the treatment of COPD and cystic fibrosis
• Ascertain the ACOS Definition and characteristics of a grey-zone syndrome, excluded from current asthma and COPD trials
• Study the role of lymphoid follicles in COPD
• Analyse airway disease endotyping for personalized therapeutics
Check online for earlybirds
Prices:
Conference + Workshop: GBP 2098+VAT
Conference Only GBP 1499+VAT
Time: 8:30 am to 5:00 pm
Speakers include:
• Frank Thielmann, Operational Lead, Inhalation New Solids, Novartis
• Philip Silkoff, Senior Medical Dir., Johnson & Johnson
• Stefano Petruzzelli, Chief Medical Officer & Dir., Global Clinical Development, Chiesi
• Sanjeeva Dissanayake, Head of Medical Sciences – Respiratory, Mundipharma
• Noel Snell, Dir. of Research, British Lung Foundation
• Geoff Down, Chief Medical Officer, Prosonix
• Konstantinos Kostikas, Medical Dir. Respiratory COPD Region Europe, Novartis
• Thomas Schlange, Senior Biomarker Expert, Bayer
• Matthew Sleeman, Senior Dir. of Biology, Respiratory, Inflammation & Autoimmunity, MedImmune
Reasons to attend:
• Gain insight into formulation developments and the manufacturing of dry powder inhalation products
• Evaluate COPD and comorbidities
• Learn about "first in class" inhaled drugs for the treatment of COPD and cystic fibrosis
• Ascertain the ACOS Definition and characteristics of a grey-zone syndrome, excluded from current asthma and COPD trials
• Study the role of lymphoid follicles in COPD
• Analyse airway disease endotyping for personalized therapeutics
Check online for earlybirds
Prices:
Conference + Workshop: GBP 2098+VAT
Conference Only GBP 1499+VAT
Time: 8:30 am to 5:00 pm
